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inezolid is the first in a new class of antimicrobials, the
oxazolidinones. This antimicrobial is approved to treat
gram-positive infections caused by vancomycin-resistant
enterococci (VRE) and methicillin-resistant Staphylococcus
aureus (MRSA) (1). Newer antibiotics have provided clini-
cians greater treatment options; however, ongoing experience
shows limitations in their use. We report two patients with
infections caused by linezolid-resistant and possible linezolid-
nonsusceptible bacteria and provide commentary on the
increasing bacterial resistance to linezolid and quinupristin/
dalfopristin, as well as the appropriate use of these and future
antibiotics. 
Patient 1
A 47-year-old man’s history was notable only for right
ankle and subtalar arthritis. He underwent right ankle fusion
with a nail placement in October 2000. In April 2001, he went
to the emergency department for ankle pain secondary to a
newly displaced fracture. The fusion nail was removed in the
operating room; placement of a new longer nail was uncompli-
cated. One month later, he developed an ankle hematoma; it
was drained, and he was given cephalexin for 7 days. Over the
next several weeks, the area became erythematous and swol-
len; it spontaneously drained purulent material. The patient
underwent irrigation and debridement on May 31, 2001. Gross
pus was obtained and sent for Gram stain and culture. The
patient was discharged with a prescription for amoxicillin/cla-
vulanate tablets. 
Culture grew S. aureus susceptible to vancomycin, trime-
thoprim/sulfamethoxazole (TMP-SMX), and gentamicin and
resistant to all beta-lactams and clindamycin. Beta-lactams
tested included penicillin, nafcillin, amoxicillin/clavulanate,
cefazolin, and imipenem. Susceptibility testing of this MRSA
isolate to linezolid was not performed. All testing was con-
ducted by using a MicroScan (Dade Behring, Inc., West Sacra-
mento, CA) automated system (unless otherwise noted) in
accordance with National Committee on for Clinical Labora-
tory Standards (NCCLS) testing and quality-control recom-
mendations (2).
Amoxicillin/clavulanate was discontinued, and oral line-
zolid, 600 mg twice a day, was begun. The patient did well,
progressing to full weight-bearing capacity, and finished a
7-week course of linezolid. Two days after completing the
course, nausea, fever, and chills developed, and he resumed
linezolid. He went to the emergency room on July 30 with a
temperature of 103°F; his ankle was warm and tender to palpa-
tion. Linezolid was stopped, and intravenous vancomycin, 1 g
every 12 hrs, was started. The nail was surgically removed,
Gram stain and cultures were obtained, and a peripherally
inserted central catheter line was placed intraoperatively. He
was continued on vancomycin. Cultures grew MRSA with the
same sensitivities as the previous MRSA isolate. Additional
susceptibility testing of this isolate to linezolid and TMP-SMX
by E-test was performed; both were susceptible (MIC=4 µg/
mL and 0.047 µg/mL, respectively). After 4 weeks, vancomy-
cin was discontinued, and oral TMP-SMX, two double-
strength tablets twice daily, was initiated for an additional 8
weeks of therapy. At followup, the patient’s laboratory results
showed a decreased leukocyte count, erythrocyte sedimenta-
tion rate, and C-reactive protein. He subsequently finished a
total of 12 weeks of therapy and remained asymptomatic 6
months after completion of treatment.
Patient 2
A 41-year-old woman with refractory acute lymphocytic
leukemia was admitted in May 2001 for an allogeneic bone
marrow transplant. Her hospital course was complicated by
Klebsiella pneumoniae sepsis, neutropenia, mental status
changes, acute renal failure, and respiratory distress. She
received several courses of antibiotics for extended periods
including imipenem, amikacin, piperacillin/tazobactam, van-
comycin, amphotericin B lipid complex, fluconazole, ciprof-
loxacin, and tobramycin. While she was receiving
vancomycin, both peripheral and central venous catheter blood
cultures grew vancomycin-resistant Enterococcus faecium
(MIC >16 g/mL). The isolate was also resistant to other antibi-
otics tested (MIC of VRE was >8 µg/mL for both ampicillin
and penicillin). Vancomycin was discontinued, intravenous
linezolid, 600 mg every 12 hrs, was begun, and susceptibility
testing to linezolid was requested. She remained on linezolid
and died 3 days later. Subsequent susceptibility results
revealed the isolate to be resistant to linezolid by E-test (MIC
= 32 µg/mL). Confirmatory testing by broth dilution and E-test
was performed at a reference lab, which verified resistance to
linezolid and intermediate susceptibility to quinupristin/dalfo-
pristin (MIC = 2 µg/mL).  *Ohio State University Medical Center, Columbus, Ohio, USA
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Patient 1, a pharmacist, preferred the convenience of oral
linezolid therapy to intravenous vancomycin. Initial suscepti-
bility of the MRSA isolate to linezolid was not obtained; how-
ever, a previous case report described success in treating
MRSA and VRE bacteremia in a patient with MRI (magnetic
resonance imagery)–confirmed vertebral osteomyelitis as the
primary focus for infection (3). Although the second MRSA
isolate in our patient was considered susceptible to linezolid
by the NCCLS-defined MIC interpretive standard (MIC
<4 µg/mL), the patient did not respond to a 7-week course of
linezolid. Of interest, the MIC of MRSA to linezolid from our
patient’s isolate was 4 µg/mL, three dilutions greater than the
isolate in the prior case report (MIC=0.5 µg/mL).
Patient 2’s treatment was changed from empiric vancomy-
cin to linezolid for VRE bacteremia without linezolid being
part of her initial susceptibility data. Only after the patient died
did the requested sensitivities to linezolid become available.
Had linezolid been part of the initial susceptibility data, other
therapies most likely would have been pursued since the iso-
late was resistant to linezolid. Arguably, her death might have
been averted. 
Multidrug-resistant organisms, especially VRE, continue
to contribute to illness and death (4,5). In a published case
series involving linezolid for 15 patients with VRE infections,
mortality was noted to be very high at long-term followup (6).
Two explanations might account for this high rate. First, the
patients identified were severely ill with several coexisting
conditions or illnesses. Second, other options were pursued
before the initiation of linezolid, which may have inadvert-
ently contributed to increased illness and death because of the
delay in giving linezolid therapy. This latter argument is sup-
ported by studies (7,8) that show a significantly greater
increase in hospital deaths if patients received inappropriate
antimicrobial therapy compared to those whose initial therapy
was appropriate. 
These data, in addition to these recent experiences, have
led us to routinely conduct susceptibility testing of linezolid
and quinupristin/dalfopristin to VRE obtained from any sterile
site. Previously, susceptibility data of linezolid and quinupris-
tin/dalfopristin to VRE or MRSA were not routinely con-
ducted unless specifically requested. Once the standard
susceptibility panel was reported, if additional susceptibility
tests were requested, they would be conducted with an E-test
(AB Biodisk North America, Inc., Piscataway, NJ). This pro-
cedure was mainly because these drugs were not yet included
on microtiter plates for commonly used automated systems
(e.g., MicroScan, Vitek), and clinical reports of resistance
were scarce. In addition, clinicians have a rather limited win-
dow of opportunity to request susceptibility testing to these
newer agents because most bacterial isolates are saved for only
5 days. Our current practice includes obtaining tests of a VRE
isolate’s susceptibility to linezolid and quinupristin/dalfopris-
tin as routine practice if the isolate is obtained from any sterile
site. As experience and reports of resistance increase, this
practice may guide appropriate therapy. Because of the large
number of S. aureus isolates resistant to methicillin submitted
to the microbiology laboratory annually, and because linezolid
nonsusceptibility to clinical isolates of MRSA has only been
reported once (9), we continue to conduct susceptibility testing
of linezolid and quinupristin/dalfopristin to MRSA isolates
only when requested. 
To make the most appropriate use of these newer antimi-
crobial agents, data on susceptibility are needed. We recom-
mend that tests for susceptibility to linezolid and quinupristin/
dalfopristin be conducted before treatment is initiated.
Although this procedure may no longer be necessary once
standardized microtiter plates include these antibiotics, it is
nevertheless relevant as clinical failures and reports of resis-
tance mount. (4,9,10) Assuming antimicrobial sensitivity
because an antibiotic is a recent addition to the antimicrobial
armamentarium may lead to increased illness, deaths, and
costs.
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